Previous 10 | Next 10 |
Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q3 GAAP EPS of -$0.87 misses by $0.08 . Cash position. Cash, cash equivalents and investments as of September 30, 2022, were $306.5 million. Shares outstanding. 67,838,803 shares of common stock were issued and...
— Positive updates from Phase 1 clinical trial in Danon Disease showed RP-A501 was well tolerated with evidence of durable treatment effect and disease improvement for both pediatric patients and adult patients with up to nine and 36 months of follow-up, respectively...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces upcoming data presentations at the 75 th Ame...
BTIG launch its coverage on clinical-stage biotech Rocket Pharmaceuticals ( NASDAQ: RCKT ) with a Buy rating and $35 per share target on Tuesday, noting its potential in the gene therapy space. The bullish call comes about a month after Rocket ( RCKT ) announced Phase ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces data presentations at the 29 th Annual Congress of the...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announced that Raj Prabhakar, M.B.A., Chief Business Officer, will d...
Rocket Pharmaceuticals ( NASDAQ: RCKT ) shares down 3.9% after-hours on pricing an underwritten public offering of 6.8M shares of its common stock at a public offering price of $14.75/share for expected gross proceeds to be $100.3M. All shares in the offering are to be...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today the pricing of an underwritten public offering...
Rocket Pharmaceuticals ( NASDAQ: RCKT ) stock slid 6.5% postmarket on Monday after the firm announced a $100M underwritten public stock offering . RCKT intends to grant underwriters a 30-day option to buy up to an additional $15M of shares. Shares of RCKT have...
Rocket Pharmaceuticals ( NASDAQ: RCKT ) said its gene therapy RP-A501 was safe, well tolerated and showed clinical benefit in two children and four adults in a phase 1 trial to treat Danon Disease (DD). DD is a rare genetic condition characterized by weakening ...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...